Feb 26, 2019
Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
CONCLUSION: The retroperitoneum is the most common site of relapse in clinical stage I NSGCT on AS. Most are cured by single-modality treatment. RPLND should be considered for relapsed patients, especially those with disease limited to the retroperitoneum and normal markers, as an option to avoid chemotherapy.